Date: 2015-10-12
Type of information: Nomination
Compound:
Company: Fate Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology - Immunological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 12, 2015, Fate Therapeutics, a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced that Scott Wolchko will succeed Christian Weyer , M.D., M.A.S., as President and Chief Executive Officer following Dr. Weyer\'s resignation effective November 30, 2015 . Mr. Wolchko , who has served as the Company\'s Chief Financial Officer since its founding and as Chief Operating Officer since January 2013 , has also joined Fate\'s Board of Directors. Mr. Wolchko founded Fate Therapeutics in 2007 with leading venture capitalists at ARCH Venture Partners , Polaris Partners and Venrock. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co.\'s Healthcare Investment Banking Group in New York and San Francisco . Prior to founding Fate Therapeutics in 2007, he helped start and served as Chief Financial Officer of Bocada, Inc. , an enterprise software company providing business intelligence solutions for data management and protection, and previously led corporate development at drugstore.com , a health and wellness internet retailer. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia , and a B.S. in biomedical engineering from the University of Vermont . In connection with Mr. Wolchko\'s new role, Fate Therapeutics also announced the following organizational changes:
- Daniel Shoemaker, Ph.D., who joined Fate Therapeutics as Chief Technology Officer in 2009, has been appointed Chief Scientific Officer. In this capacity, Dr. Shoemaker will lead the Company\'s scientific strategy and research operations, and will be responsible for identifying and developing modulators of immune cells, conducting preclinical and translational clinical research and overseeing external research collaborations.
- Stewart Abbot, Ph.D., who joined Fate Therapeutics as Vice President, Translational Research in 2015, has been appointed Chief Development Officer. Dr. Abbot joined Fate Therapeutics from Celgene Cellular Therapeutics (CCT), where he was instrumental in developing CCT\'s hematopoietic cell-based immuno-oncology programs and partnerships. In his capacity as Chief Development Officer, Dr. Abbot will lead early development strategy, and will be responsible for defining preclinical candidates and early development pathways and for advancing preclinical candidates into first-in-human clinical studies.
- Cindy Tahl, J.D., who joined Fate Therapeutics in 2009, has been appointed General Counsel. During her tenure at Fate Therapeutics , Ms. Tahl has served as the Company\'s senior legal counsel, providing legal advice across all functions of the business and overseeing all corporate compliance matters, and has led the development of the Company\'s intellectual property strategy. Ms. Tahl is admitted to the State Bars of California and New York .
Financial terms:
Latest news:
